PFIZER INC reported first-quarter revenue of $14.45 billion on Tuesday, exceeding analyst estimates of $13.79 billion. The results reflect a 22% growth in newly launched and acquired medicines, helping the drugmaker offset a 59% decline in COVID-19 vaccine sales. Investors are monitoring the company's ability to bridge revenue gaps before major patent expirations and obesity drug launches slated for 2028.

Portfolio Gains Offset COVID Decline